FIELD: chemistry.
SUBSTANCE: invention relates to biotechnology. Disclosed are methods for clostridial toxin activation. Double expression product, containing TEV protease open reading frame and single-stranded clostridial toxin or protein frame, is inserted into cell. Cells are grown in two stages. First stage is 37°C, second stage is 22°C or 16°C.
EFFECT: invention makes it possible to obtain clostridal toxin activated inside cell.
15 cl, 2 dwg, 4 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DEGRADABLE CLOSTRIDIAL TOXINS | 2011 |
|
RU2561465C2 |
| RECOMBINANT PROTEIN EXPRESSION IN DOUBLE-STRAND C FORM | 2006 |
|
RU2412253C2 |
| FUSION PROTEINS AND METHODS OF TREATMENT, PREVENTION OR ALLEVIATION OF PAIN | 2013 |
|
RU2652954C2 |
| THERAPEUTIC FUSION PROTEINS | 2012 |
|
RU2651492C2 |
| CATIONIC NEUROTOXINS | 2015 |
|
RU2733493C2 |
| NEUROTOXINS THAT DISPLAY REDUCED BIOLOGICAL ACTIVITY | 2010 |
|
RU2582266C2 |
| SORTASE-LABELED CLOSTRIDIA NEUROTOXINS | 2020 |
|
RU2801120C2 |
| GENETICALLY ENGINEERED CELLS SENSITIVE TO CLOSTRIDIAL NEUROTOXINS | 2020 |
|
RU2824389C2 |
| METHOD OF TREATING URINOGENITAL NEUROLOGICAL DISORDERS WITH USING MODIFIED CLOSTRIDIAL TOXINS | 2008 |
|
RU2491086C2 |
| NEUROTOXINS SHOWING SHORTENED BIOLOGICAL ACTIVITY | 2012 |
|
RU2646110C2 |
